Gene therapy advances as scientists guide jumping DNA to target faulty genes

JABSOM Cell and Molecular Biology researcher Dr. Jesse Owens has spent the better part of two decades chasing a vision that ...

Spot the males: New gene-editing method could transform mosquito control

Researchers have developed a new "color-coded" genetic method that makes it easy to distinguish male and female mosquitoes.
Interesting Engineering

Scientists identify a non-coding gene that directly controls how big cells grow

Scientists identify the first non-coding gene that directly controls cell size, reshaping how biology explains growth and ...

Scientists identify first non-coding gene that controls cell size

What keeps our cells the right size? Scientists have long puzzled over this fundamental question, since cells that are too ...
WebMD

Itvisma: FDA Approves One-Time Gene Therapy for Spinal Muscular Atrophy in Children 2 or Older, Teens, and Adults

What Is Itvisma, and Why Does It Matter? Itvisma (onasemnogene abeparvovec-brve) is a gene therapy that the FDA has approved to treat spinal muscular atrophy (SMA) in adults, teens, and children 2 or ...
Benzinga.com

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

On Monday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE: NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and older, teens, and adults with spinal ...
BioSpace

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

“The FDA’s approval of intrathecal onasemnogene abeparvovec is a game-changing advance, expanding the use of transformational gene replacement therapy for SMA across age groups,” said John W. Day, MD, ...
SMA

FDA approves SMA gene therapy Itvisma for patients 2 and older

FDA approved Itvisma, a gene therapy for SMA patients aged 2 and older. Itvisma delivers a healthy SMN1 gene via spinal injection in a one-time treatment. This expands gene therapy access to older ...
journalgazette

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

EAST HANOVER, N.J., Nov. 24, 2025 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma ® (onasemnogene abeparvovec-brve) for the treatment of ...
The Daily Review

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time dose of Itvisma replaces ...